JP2019507775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507775A5 JP2019507775A5 JP2018546897A JP2018546897A JP2019507775A5 JP 2019507775 A5 JP2019507775 A5 JP 2019507775A5 JP 2018546897 A JP2018546897 A JP 2018546897A JP 2018546897 A JP2018546897 A JP 2018546897A JP 2019507775 A5 JP2019507775 A5 JP 2019507775A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- subject
- composition according
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 12
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 8
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 8
- 206010003246 arthritis Diseases 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000004062 sedimentation Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022170275A JP7745529B2 (ja) | 2016-03-07 | 2022-10-25 | 関節リウマチを処置するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305253.3 | 2016-03-07 | ||
| EP16305253.3A EP3216461A1 (en) | 2016-03-07 | 2016-03-07 | Compositions and methods for treating rheumatoid arthritis |
| EP16170664 | 2016-05-20 | ||
| EP16170664.3 | 2016-05-20 | ||
| EP16306111 | 2016-09-05 | ||
| EP16306111.2 | 2016-09-05 | ||
| PCT/US2017/021149 WO2017155990A1 (en) | 2016-03-07 | 2017-03-07 | Compositions and methods for treating rheumatoid arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022170275A Division JP7745529B2 (ja) | 2016-03-07 | 2022-10-25 | 関節リウマチを処置するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507775A JP2019507775A (ja) | 2019-03-22 |
| JP2019507775A5 true JP2019507775A5 (enExample) | 2020-04-09 |
| JP7166925B2 JP7166925B2 (ja) | 2022-11-08 |
Family
ID=58387910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546897A Active JP7166925B2 (ja) | 2016-03-07 | 2017-03-07 | 関節リウマチを処置するための組成物及び方法 |
| JP2022170275A Active JP7745529B2 (ja) | 2016-03-07 | 2022-10-25 | 関節リウマチを処置するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022170275A Active JP7745529B2 (ja) | 2016-03-07 | 2022-10-25 | 関節リウマチを処置するための組成物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190100585A1 (enExample) |
| EP (1) | EP3426295A1 (enExample) |
| JP (2) | JP7166925B2 (enExample) |
| KR (3) | KR20230093522A (enExample) |
| CN (1) | CN109069642A (enExample) |
| AU (2) | AU2017229364A1 (enExample) |
| BR (1) | BR112018067851A2 (enExample) |
| CA (1) | CA3016880A1 (enExample) |
| CL (1) | CL2018002559A1 (enExample) |
| CR (1) | CR20180465A (enExample) |
| EA (1) | EA201892005A1 (enExample) |
| IL (2) | IL308539A (enExample) |
| MX (2) | MX2018010815A (enExample) |
| PH (1) | PH12018501894A1 (enExample) |
| SG (2) | SG10202012182YA (enExample) |
| TN (1) | TN2018000312A1 (enExample) |
| TW (3) | TWI747885B (enExample) |
| WO (1) | WO2017155990A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| MX2020005630A (es) * | 2017-11-30 | 2020-08-20 | Bio Thera Solutions Ltd | Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6. |
| KR20260109977A (ko) | 2018-08-29 | 2026-07-13 | 리제너론 파아마슈티컬스, 인크. | 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물 |
| JP7542543B2 (ja) | 2019-01-31 | 2024-08-30 | サノフィ・バイオテクノロジー | 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体 |
| JP2022545312A (ja) | 2019-04-24 | 2022-10-27 | サノフィ・バイオテクノロジー | 関節リウマチの診断及び処置の方法 |
| CA3142710A1 (en) * | 2019-06-04 | 2020-12-10 | Sanofi Biotechnology | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| WO2023020563A1 (en) * | 2021-08-18 | 2023-02-23 | Bio-Thera Solutions, Ltd. | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
| WO2026047197A1 (en) | 2024-08-30 | 2026-03-05 | Sanofi Biotechnology | Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
| CA2817619A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| GB0718684D0 (en) * | 2007-09-24 | 2007-10-31 | Roche Products Ltd | Treatment method |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
| US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
| KR20230155586A (ko) * | 2013-11-22 | 2023-11-10 | 사노피 바이오테크놀로지 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
-
2017
- 2017-03-07 KR KR1020237019726A patent/KR20230093522A/ko not_active Ceased
- 2017-03-07 IL IL308539A patent/IL308539A/en unknown
- 2017-03-07 US US16/082,841 patent/US20190100585A1/en active Pending
- 2017-03-07 AU AU2017229364A patent/AU2017229364A1/en not_active Abandoned
- 2017-03-07 KR KR1020187028624A patent/KR20180114955A/ko not_active Ceased
- 2017-03-07 TW TW106107363A patent/TWI747885B/zh active
- 2017-03-07 CN CN201780028050.2A patent/CN109069642A/zh active Pending
- 2017-03-07 IL IL261515A patent/IL261515B2/en unknown
- 2017-03-07 JP JP2018546897A patent/JP7166925B2/ja active Active
- 2017-03-07 TW TW110146922A patent/TWI819435B/zh active
- 2017-03-07 WO PCT/US2017/021149 patent/WO2017155990A1/en not_active Ceased
- 2017-03-07 CA CA3016880A patent/CA3016880A1/en active Pending
- 2017-03-07 TN TNP/2018/000312A patent/TN2018000312A1/en unknown
- 2017-03-07 EA EA201892005A patent/EA201892005A1/ru unknown
- 2017-03-07 SG SG10202012182YA patent/SG10202012182YA/en unknown
- 2017-03-07 BR BR112018067851A patent/BR112018067851A2/pt not_active Application Discontinuation
- 2017-03-07 TW TW112135625A patent/TW202419103A/zh unknown
- 2017-03-07 CR CR20180465A patent/CR20180465A/es unknown
- 2017-03-07 KR KR1020267009842A patent/KR20260049875A/ko active Pending
- 2017-03-07 SG SG11201807614SA patent/SG11201807614SA/en unknown
- 2017-03-07 EP EP17712604.2A patent/EP3426295A1/en active Pending
- 2017-03-07 MX MX2018010815A patent/MX2018010815A/es unknown
-
2018
- 2018-09-05 PH PH12018501894A patent/PH12018501894A1/en unknown
- 2018-09-07 MX MX2023014841A patent/MX2023014841A/es unknown
- 2018-09-07 CL CL2018002559A patent/CL2018002559A1/es unknown
-
2022
- 2022-10-25 JP JP2022170275A patent/JP7745529B2/ja active Active
-
2024
- 2024-05-07 AU AU2024203011A patent/AU2024203011A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | Effect of IL-17A blockade with secukinumab in autoimmune diseases | |
| Riese et al. | Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes | |
| Gizinski et al. | T cell subsets and their role in the pathogenesis of rheumatic disease | |
| Kremer et al. | A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone | |
| Lim et al. | Biologic therapies for inflammatory eye disease | |
| Mahajan et al. | Recent advances in the treatment of rheumatoid arthritis | |
| Ma et al. | TNF inhibitor therapy for rheumatoid arthritis | |
| Schaap-Fogler et al. | Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis | |
| US20200282051A1 (en) | Jak inhibitors and uses thereof | |
| JP7101479B2 (ja) | 関節リウマチ患者の健康に関連した生活の質を改善するための組成物 | |
| Hazirolan et al. | Light on the horizont: biologicals in Behçet uveitis | |
| Neri et al. | Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology | |
| Takeuchi et al. | Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate | |
| Roeleveld et al. | The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders | |
| So et al. | An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis | |
| JP2022502350A5 (enExample) | ||
| Steele et al. | Targeting TL1A/DR3 signaling offers a therapeutic advantage to neutralizing IL13/IL4Rα in muco-secretory fibrotic disorders | |
| CA2944811A1 (en) | Combination therapy for the treatment of autoimmune diseases | |
| MX2023014841A (es) | Composiciones para tratar artritis reumatoide. | |
| JP2024023347A5 (enExample) | ||
| Benitah et al. | The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease | |
| Li et al. | Indications and effects of biological agents in the treatment of noninfectious uveitis | |
| Bhat et al. | Intravenous daclizumab for recalcitrant ocular inflammatory disease | |
| JP2022534794A5 (enExample) | ||
| JP2021522241A5 (enExample) |